• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Antidepressant could stop deadly sepsis, study suggests

Bioengineer by Bioengineer
February 14, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Previous FDA approval could fast-track new treatment

IMAGE

Credit: Dan Addison | University Communications


An antidepressant drug used to treat obsessive-compulsive disorder could save people from deadly sepsis, new research from the University of Virginia School of Medicine suggests.

Sepsis is a significant cause of death around the world. The federal Centers for Disease Control and Infection calls it “the body’s extreme response to an infection.” Essentially, the body’s immune response spirals out of control, and the normally beneficial inflammation becomes harmful. The result can be tissue damage, organ failure or even death.

“Sepsis is very dangerous. In the U.S., 1.7 million get it every year, and 270,000 people die,” said researcher Alban Gaultier, PhD, of UVA’s Department of Neuroscience and its Center for Brain Immunology and Glia (BIG). “Once you get diagnosed, you have a high chance of mortality. And there is no good treatment. Basically, we will try to keep you alive and monitor you as much as we can. So clearly there is a critical need for treatment.”

Gaultier and his team have identified a drug that could offer that treatment – and previous safety testing of the drug could fast-track it into use in hospitals around the country.

A Simple Solution for Sepsis?

The UVA researchers were looking at a little-studied biological process inside our cells when they determined it has an important role in regulating inflammation. They began studying it partly because there are already drugs that can affect players in the process.

“Inflammation, most of the time, is good. It’s when it gets out of control that we need to modulate it,” Gaultier said. “Inflammation is a very precisely controlled reaction. When we need it and have too much, it’s a problem, but when we don’t have enough, it’s also a problem.”

To evaluate the potential of one drug, the antidepressant fluvoxamine, to stop sepsis, Gaultier’s team tested it in a mouse model of the disease. The drug worked very effectively, they found.

While the drug will need to be tested in people to determine its effectiveness at battling human sepsis, previous testing to determine its safety should accelerate that process.

Gaultier hypothesizes that the same biological process could be targeted to generate beneficial inflammation when needed, such as in immunocompromised people. “By inhibiting the receptor, we could activate inflammation in conditions where patient don’t have a proper inflammatory response,” he said.

He plans to continue his research, including testing that hypothesis.

###

Sepsis Findings Published

The researchers have published their findings in Science Translational Medicine. The research team consisted of Dorian A Rosen, Scott M. Seki, Anthony Ferna?ndez-Castan?eda, Rebecca M. Beiter, Jacob D. Eccles, Judith A. Woodfolk and Gaultier.

The work was supported by the National Institutes of Health, grants R01 NS083542, R21 NS101281 and T32 GM007055; and the Owens Family Foundation.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.

Media Contact
Josh Barney
[email protected]
434-906-8864

Original Source

https://newsroom.uvahealth.com/2019/02/13/antidepressant_to_stop_sepsis/

Related Journal Article

http://dx.doi.org/10.1126/scitranslmed.aau5266

Tags: Critical Care/Emergency MedicineDeath/DyingDepression/AngerGerontologyInfectious/Emerging DiseasesInternal MedicineMedicine/HealthMental HealthneurobiologySocial/Behavioral Science
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Birth Weight Linked to Maternal, Neonatal PFOS Levels

August 22, 2025
Chinese Neurosurgical Journal Highlights Rare Central Nervous System Tumor Study

Chinese Neurosurgical Journal Highlights Rare Central Nervous System Tumor Study

August 22, 2025

Protein Landscape Reveals Host Response in Emergency Patients

August 22, 2025

Exploring Cardiovascular Health Disparities Across Race and Gender in Medicare Fee-for-Service Populations

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Birth Weight Linked to Maternal, Neonatal PFOS Levels

β-Elemene’s Therapeutic Promise for Glioma, CNS Diseases

Wireless Contact Lenses: Enabling Eye-Machine Interaction Through Blink-Based Encoding

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.